ReviewCells2025
Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure.
Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SGLT2 Inhibitors and Liver Cirrhosis: Hype or Hope?Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus affects nearly 7% of the world's population and is a significant contributor to the development of cardiovascular disease and heart failure. Historically, the pharmacologic therapy of cardiovascular disease has centered around blood pressure control, insulin and cholesterol management, the inhibition of the renin-angiotensin system, and catecholamine blockade. Recent evidence suggests that sodium-glucose cotransporter 2 (SGLT-2) inhibitors provide significant cardiovascular protection to patients with and without diabetes. The use of SGLT-2 inhibitors is associated with significant changes to serum biomarkers of cardiac function. In this narrative review, we summarize how biomarkers reflect physiologic aspects of cardiovascular function and how these are affected by the use of SGLT-2 inhibitors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.